Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

CXCR4 antagonist

DRUG CLASS:

CXCR4 antagonist

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	POL 6326 Sensitive: B - Late Trials POL 6326 Sensitive : B	POL 6326 Sensitive: B - Late Trials POL 6326 Sensitive : B
CXCR4 mutation	Waldenstrom Macroglobulinemia	CXCR4 mutation	Waldenstrom Macroglobulinemia	ibrutinib + BMS-936564 Sensitive: C2 – Inclusion Criteria ibrutinib + BMS-936564 Sensitive : C2	ibrutinib + BMS-936564 Sensitive: C2 – Inclusion Criteria ibrutinib + BMS-936564 Sensitive : C2
CXCR4 positive	HER2 Negative Breast Cancer	CXCR4 positive	HER2 Negative Breast Cancer	POL 6326 Sensitive: C3 – Early Trials POL 6326 Sensitive : C3	POL 6326 Sensitive: C3 – Early Trials POL 6326 Sensitive : C3
CXCR4 mutation	Waldenstrom Macroglobulinemia	CXCR4 mutation	Waldenstrom Macroglobulinemia	ibrutinib + mavorixafor Sensitive: C3 – Early Trials ibrutinib + mavorixafor Sensitive : C3	ibrutinib + mavorixafor Sensitive: C3 – Early Trials ibrutinib + mavorixafor Sensitive : C3
MYD88 L265P	Waldenstrom Macroglobulinemia	MYD88 L265P	Waldenstrom Macroglobulinemia	mavorixafor Sensitive: C3 – Early Trials mavorixafor Sensitive : C3	mavorixafor Sensitive: C3 – Early Trials mavorixafor Sensitive : C3
CXCR4 expression	HER2 Negative Breast Cancer	CXCR4 expression	HER2 Negative Breast Cancer	POL 6326 Sensitive: C3 – Early Trials POL 6326 Sensitive : C3	POL 6326 Sensitive: C3 – Early Trials POL 6326 Sensitive : C3
MYD88 mutation + CXCR4 mutation	Waldenstrom Macroglobulinemia	MYD88 mutation + CXCR4 mutation	Waldenstrom Macroglobulinemia	ibrutinib + mavorixafor Sensitive: C3 – Early Trials ibrutinib + mavorixafor Sensitive : C3	ibrutinib + mavorixafor Sensitive: C3 – Early Trials ibrutinib + mavorixafor Sensitive : C3
FLT3-ITD mutation + WT1 mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation + WT1 mutation	Acute Myelogenous Leukemia	sorafenib + GMI-1359 Sensitive: D – Preclinical sorafenib + GMI-1359 Sensitive : D	sorafenib + GMI-1359 Sensitive: D – Preclinical sorafenib + GMI-1359 Sensitive : D
WT1 mutation	Acute Myelogenous Leukemia	WT1 mutation	Acute Myelogenous Leukemia	sorafenib + GMI-1359 Sensitive: D – Preclinical sorafenib + GMI-1359 Sensitive : D	sorafenib + GMI-1359 Sensitive: D – Preclinical sorafenib + GMI-1359 Sensitive : D
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	sorafenib + GMI-1359 Sensitive: D – Preclinical sorafenib + GMI-1359 Sensitive : D	sorafenib + GMI-1359 Sensitive: D – Preclinical sorafenib + GMI-1359 Sensitive : D
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	quizartinib + LY2510924 Sensitive: D – Preclinical quizartinib + LY2510924 Sensitive : D	quizartinib + LY2510924 Sensitive: D – Preclinical quizartinib + LY2510924 Sensitive : D
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	quizartinib + GMI-1359 Sensitive: D – Preclinical quizartinib + GMI-1359 Sensitive : D	quizartinib + GMI-1359 Sensitive: D – Preclinical quizartinib + GMI-1359 Sensitive : D